Structures by: Ellena J.
Total: 217
(+-)-3-<i>tert</i>-Butyl-4-(4-chlorophenyl)-1-phenyl-1<i>H</i>-pyrazolo[3,4-<i>e</i>][1,4]thiazepin-7(4<i>H</i>,6<i>H</i>,8<i>H</i>)-one
C22H22ClN3OS
IUCrData (2016) 1, 4 x160608
a=9.7478(3)Å b=25.2229(8)Å c=8.6354(2)Å
α=90° β=101.733(2)° γ=90°
Li2 Ca Hf F8
CaF8HfLi2
Journal of Physics: Condensed Matter (2002) 14, 5485-5495
a=5.1063Å b=5.1063Å c=10.5248Å
α=90° β=90° γ=90°
Na Ca Mg2 F7
CaF7Mg2Na
Journal of Solid State Chemistry (2004) 177, 2943-2950
a=10.261Å b=10.261Å c=10.261Å
α=90° β=90° γ=90°
MFNCu1
C8H22CuN10,2(Cl),2(H2O)
RSC Advances (2020) 10, 38 22856-22863
a=5.1596(14)Å b=11.562(2)Å c=15.091(4)Å
α=90° β=95.63(3)° γ=90°
MetZn
C4H12Cl3N5Zn
RSC Advances (2020) 10, 38 22856-22863
a=12.5200(12)Å b=7.5140(6)Å c=13.0298(13)Å
α=90° β=113.199(12)° γ=90°
2(C8H21N10Ni),2(Cl),2(H2O)
2(C8H21N10Ni),2(Cl),2(H2O)
RSC Advances (2020) 10, 38 22856-22863
a=13.3863(6)Å b=14.8373(9)Å c=15.7512(9)Å
α=90° β=104.757(5)° γ=90°
C12H33CoN15,2(Cl),H2O
C12H33CoN15,2(Cl),H2O
RSC Advances (2020) 10, 38 22856-22863
a=36.470(2)Å b=8.5892(6)Å c=17.3656(13)Å
α=90° β=99.376(6)° γ=90°
DS05
C51H52AgClN4O3P2S,0.25[C2H3N]
Dalton transactions (Cambridge, England : 2003) (2020) 49, 45 16474-16487
a=25.4270(9)Å b=12.1243(5)Å c=33.2299(10)Å
α=90° β=100.785(3)° γ=90°
DES 6
C52H54AgClN4O2P2S
Dalton transactions (Cambridge, England : 2003) (2020) 49, 45 16474-16487
a=25.5169(10)Å b=10.2681(3)Å c=43.6410(13)Å
α=90° β=102.951(3)° γ=90°
Bi[s(acetonitrile)bis[diphenylphosphanyl)2-benzyl]trichlorodiruthenium tetrafluo
C66H60BCl3F4N4P4Ru2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 45 16498-16514
a=10.8878(5)Å b=19.1910(9)Å c=31.0546(13)Å
α=90° β=98.354(2)° γ=90°
C41H41.5BClF4NO0.25P2Ru
C41H41.5BClF4NO0.25P2Ru
Dalton transactions (Cambridge, England : 2003) (2020) 49, 45 16498-16514
a=10.7960(6)Å b=12.2360(7)Å c=15.3090(5)Å
α=96.965(3)° β=91.221(3)° γ=97.427(2)°
CMS31
C14H7EuN2O8
New Journal of Chemistry (2020) 44, 24 10146-10152
a=12.2655(3)Å b=8.3615(2)Å c=13.5192(3)Å
α=90° β=102.388(3)° γ=90°
C43H40N4O2P2Ru,3(H2O)
C43H40N4O2P2Ru,3(H2O)
New Journal of Chemistry (2018) 42, 9 6794
a=18.3197(7)Å b=12.5109(7)Å c=19.7938(16)Å
α=90° β=116.165(3)° γ=90°
Timcwbipy
C51H43N4O2P2Ru,F6P
New Journal of Chemistry (2018) 42, 9 6794
a=13.1070(11)Å b=13.7330(7)Å c=14.6080(9)Å
α=81.323(3)° β=70.114(4)° γ=75.816(3)°
5-Fluorocytosine; 5-Flucytosine; 5-FC; 5FC-PABA
C4H4FN3O,C7H7NO2
New Journal of Chemistry (2018) 42, 18 14994
a=4.8695(3)Å b=24.4911(16)Å c=9.8792(6)Å
α=90° β=97.567(6)° γ=90°
5-Fluorocytosine; 5-Flucytosine; 5-FC; 5FC-CAF
2(C4H4FN3O),2(C8H10N4O2)
New Journal of Chemistry (2018) 42, 18 14994
a=9.1890(6)Å b=22.4128(17)Å c=13.3425(13)Å
α=90° β=93.485(8)° γ=90°
5-Fluorocytosine; 5-Flucytosine; 5-FC; 5FC-CA
C4H4FN3O,C8H16O2
New Journal of Chemistry (2018) 42, 18 14994
a=5.2617(8)Å b=8.7066(14)Å c=15.710(2)Å
α=81.892(3)° β=85.884(3)° γ=84.460(3)°
5-FC, 5-Fluorocytosine, Fluorocytosine, FCDNS
C11H10FN5O9
New Journal of Chemistry (2019) 43, 40 15924
a=21.337(3)Å b=5.4905(9)Å c=12.445(2)Å
α=90° β=103.196(3)° γ=90°
2FCPA, Fluorocytosine, 5-FC, 5-Fluorocytosine
C14H11F2N9O9
New Journal of Chemistry (2019) 43, 40 15924
a=8.4380(2)Å b=10.6270(3)Å c=11.2100(3)Å
α=76.3720(10)° β=87.981(2)° γ=73.180(2)°
2,3,7-Triphenylcyclopenta[c]pyran
C26H18O
New Journal of Chemistry (2001) 25, 11 1472
a=8.2130(4)Å b=9.9120(4)Å c=11.5310(5)Å
α=98.303(2)° β=94.060(3)° γ=96.414(2)°
2(C14H24N4O20Y2),1.5(H4O2)
2(C14H24N4O20Y2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.0910(2)Å b=11.3880(3)Å c=13.4790(4)Å
α=73.4220(10)° β=69.6950(10)° γ=63.977(2)°
2(C14H24N4O20Yb2),1.5(H4O2)
2(C14H24N4O20Yb2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.3050(4)Å b=11.5990(4)Å c=13.7310(6)Å
α=73.850(2)° β=70.201(2)° γ=64.115(2)°
2(C14H24N4O20Tb2),1.5(H4O2)
2(C14H24N4O20Tb2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.1280(2)Å b=11.4150(3)Å c=13.5200(4)Å
α=73.404(2)° β=69.8080(10)° γ=63.993(2)°
2(C14H24N4O20Tm2),1.5(H4O2)
2(C14H24N4O20Tm2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.0560(3)Å b=11.3660(3)Å c=13.4310(2)Å
α=73.444(2)° β=69.550(2)° γ=63.9850(10)°
2(C14H24N4O20Sm2),1.5(H4O2)
2(C14H24N4O20Sm2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.1870(2)Å b=11.4690(2)Å c=13.5920(3)Å
α=73.4700(10)° β=69.9100(10)° γ=64.0200(10)°
2(C14H24N4O20Pr2),1.5(H4O2)
2(C14H24N4O20Pr2),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.2460(2)Å b=11.5340(2)Å c=13.6610(4)Å
α=73.6620(10)° β=70.046(2)° γ=64.068(2)°
2(C14H24N4Nd2O20),1.5(H4O2)
2(C14H24N4Nd2O20),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.22400(10)Å b=11.50800(10)Å c=13.6380(2)Å
α=73.6180(10)° β=70.0120(10)° γ=64.0480(10)°
2(C14H24La2N4O20),1.5(H4O2)
2(C14H24La2N4O20),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.3050(4)Å b=11.5990(4)Å c=13.7310(6)Å
α=73.850(2)° β=70.201(2)° γ=64.115(2)°
2(C14H24Ho2N4O20),1.5(H4O2)
2(C14H24Ho2N4O20),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.0930(2)Å b=11.3850(2)Å c=13.4770(3)Å
α=73.3940(10)° β=69.7240(10)° γ=63.9800(10)°
2(C14H24Gd2N4O20),1.5(H4O2)
2(C14H24Gd2N4O20),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.1500(2)Å b=11.4340(2)Å c=13.5500(2)Å
α=73.4450(10)° β=69.8410(10)° γ=63.9910(10)°
2(C14H24Er2N4O20),1.5(H4O2)
2(C14H24Er2N4O20),1.5(H4O2)
New J. Chem. (2016) 40, 6 5338
a=10.0740(2)Å b=11.3710(3)Å c=13.4560(3)Å
α=73.413(2)° β=69.6580(10)° γ=63.9770(10)°
Dysuc1
2(C14H24Dy2N4O20),3(H2O)
New J. Chem. (2016) 40, 6 5338
a=10.1090(3)Å b=11.3990(3)Å c=13.4990(4)Å
α=73.409(2)° β=69.756(2)° γ=63.988(2)°
2(C14H24Ce2N4O20),3(H2O)
2(C14H24Ce2N4O20),3(H2O)
New J. Chem. (2016) 40, 6 5338
a=10.2740(2)Å b=11.56400(10)Å c=13.6900(2)Å
α=73.7490(10)° β=70.1140(10)° γ=64.0920(10)°
C13H13F2N6O,C2HO4
C13H13F2N6O,C2HO4
CrystEngComm (2019) 21, 7 1114
a=5.6109(6)Å b=14.9140(18)Å c=20.848(3)Å
α=90° β=96.566(6)° γ=90°
PRX-FUM
C19H21FNO3,C4H3O4
CrystEngComm (2019) 21, 24 3668
a=7.2223(3)Å b=7.9950(10)Å c=18.538(2)Å
α=78.672(10)° β=82.396(5)° γ=85.860(7)°
PRX-OXA
C2O4,2(C19H21FNO3),0.5(O2H4)
CrystEngComm (2019) 21, 24 3668
a=18.960(3)Å b=6.7993(11)Å c=29.935(5)Å
α=90° β=91.638(14)° γ=90°
PRX-TART
0.5(C4H4O6),0.5(C4H6O6),C19H21FNO3,0.5(H2O)
CrystEngComm (2019) 21, 24 3668
a=14.3395(17)Å b=7.9557(9)Å c=19.608(2)Å
α=90° β=97.036(2)° γ=90°
PRX-MAL
C19H21FNO3,C4H3O4
CrystEngComm (2019) 21, 24 3668
a=11.629(2)Å b=11.649(2)Å c=17.584(5)Å
α=77.740(4)° β=77.333(4)° γ=71.079(3)°
Ticlopidine hydrochloride form II
C14H15Cl2NS
CrystEngComm (2011) 13, 19 5737
a=5.4410(2)Å b=12.2260(4)Å c=21.7050(7)Å
α=90° β=101.040(2)° γ=90°
Chlortalidone Form IV
4(C14H11ClN2O4S),CHCl3
CrystEngComm (2012) 14, 19 6173
a=7.763(2)Å b=12.938(5)Å c=17.221(7)Å
α=72.48(2)° β=87.107(16)° γ=86.201(17)°
4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl) - (1H)-pyrimidin-2-one hydrochloride
C8H12N3O3S,Cl
CrystEngComm (2012) 14, 7 2373
a=5.7060(2)Å b=11.9670(5)Å c=8.3401(4)Å
α=90.00° β=104.273(2)° γ=90.00°
4-amino-1-((2R,5S)-2-(hydroxymethyl)-1, 3-oxathiolan-5-yl)- (1H)-pyrimidin-2-one hydrochloride monohydrate
C8H12N3O3S,H2O,Cl
CrystEngComm (2012) 14, 7 2373
a=5.2927(2)Å b=17.2524(12)Å c=6.8518(4)Å
α=90.00° β=98.865(3)° γ=90.00°
4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl) - (1H)-pyrimidin-2-one hydrochloride
C8H12N3O3S,Cl
CrystEngComm (2012) 14, 7 2373
a=5.6520(3)Å b=11.9240(6)Å c=8.3220(6)Å
α=90.00° β=104.760(3)° γ=90.00°
4-amino-1-((2R,5S)-2-(hydroxymethyl)-1, 3-oxathiolan-5-yl)- (1H)-pyrimidin-2-one hydrochloride monohydrate
C8H12N3O3S,H2O,Cl
CrystEngComm (2012) 14, 7 2373
a=5.2554(1)Å b=17.1944(6)Å c=6.8210(2)Å
α=90.0000° β=98.774(2)° γ=90.0000°
Trans-1,4bis(diphenylphosphine)-4-methylpyridinetrichlororuthenium(III)
C34H34.5Cl3NP2Ru0.5(CH2Cl2)
Journal of the Chemical Society, Dalton Transactions (2000) 19 3383
a=14.785(10)Å b=17.559(5)Å c=27.448(5)Å
α=90° β=90° γ=90°
C6H9N3O,O4S,0.5(H2O)
C6H9N3O,O4S,0.5(H2O)
CrystEngComm (2016) 18, 34 6378
a=6.9562(3)Å b=19.7321(8)Å c=13.4459(6)Å
α=90° β=93.4175(13)° γ=90°
C6H8N3O,Br
C6H8N3O,Br
CrystEngComm (2016) 18, 34 6378
a=6.6307(4)Å b=16.3280(13)Å c=7.4836(5)Å
α=90° β=92.183(7)° γ=90°
C6H9N3O1,O4S
C6H9N3O1,O4S
CrystEngComm (2016) 18, 34 6378
a=7.3259(2)Å b=6.3982(2)Å c=19.5779(7)Å
α=90° β=98.2460(10)° γ=90°
C4H5ClInNO4
C4H5ClInNO4
Dalton transactions (Cambridge, England : 2003) (2018) 47, 6 1808-1818
a=13.5719(4)Å b=8.7940(3)Å c=6.0584(2)Å
α=90° β=90° γ=90°
C18H16BiN4O8
C18H16BiN4O8
Dalton transactions (Cambridge, England : 2003) (2018) 47, 6 1808-1818
a=9.3852(6)Å b=9.6474(7)Å c=13.4442(9)Å
α=72.378(6)° β=74.943(6)° γ=62.844(7)°
C8H11BiN2O8
C8H11BiN2O8
Dalton transactions (Cambridge, England : 2003) (2018) 47, 6 1808-1818
a=18.337(5)Å b=12.223(3)Å c=10.707(3)Å
α=90° β=104.479(9)° γ=90°
C15H11N2O5Zn
C15H11N2O5Zn
Dalton transactions (Cambridge, England : 2003) (2018) 47, 6 1808-1818
a=7.6958(6)Å b=8.8864(7)Å c=10.6748(9)Å
α=80.941(7)° β=70.420(8)° γ=78.138(7)°
C44H36N4P2RuS2
C44H36N4P2RuS2
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 6026-6039
a=11.1851(2)Å b=13.2033(3)Å c=14.8420(4)Å
α=77.0840(10)° β=71.3120(10)° γ=66.439(2)°
C35H32N4P2RuS2
C35H32N4P2RuS2
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 6026-6039
a=11.1616(4)Å b=11.3093(4)Å c=14.4332(4)Å
α=90.5870(10)° β=104.7410(10)° γ=111.1510(10)°
C54H47ClN2P4RuS
C54H47ClN2P4RuS
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 6026-6039
a=21.538(1)Å b=11.555(1)Å c=22.094(1)Å
α=90.00° β=110.008(4)° γ=90.00°
C56H51F6N2P5RuS
C56H51F6N2P5RuS
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 6026-6039
a=13.9790(4)Å b=20.0910(10)Å c=21.1490(10)Å
α=90.00° β=92.913(2)° γ=90.00°
Trans-K{[FeCl(NO^0^)(cyclam)].[FeCl(NO^+^)(cyclam)]~2~}(PF~6~)~6~
C15H36Cl1.5F18Fe1.5K0.5N7.5O1.5P3
Journal of the Chemical Society, Dalton Transactions (2002) 9 1903
a=10.3560(3)Å b=17.7110(6)Å c=17.9480(6)Å
α=90.00° β=91.052(2)° γ=90.00°
Zalcitabine hydrochloride
C9H14N3O3,Cl
CrystEngComm (2014) 16, 30 7013
a=5.5482(2)Å b=12.0260(5)Å c=8.5725(3)Å
α=90.00° β=104.6393(24)° γ=90.00°
Zalcitabine hydrochloride
C9H14N3O3,Cl
CrystEngComm (2014) 16, 30 7013
a=5.4672(20)Å b=11.9780(29)Å c=8.5397(20)Å
α=90.00° β=105.3269(18)° γ=90.00°
Lamivudine zalcitabine hydrochloride
C9H14N3O3,C8H12N3O3S,2(Cl)
CrystEngComm (2014) 16, 30 7013
a=6.692(1)Å b=8.886(1)Å c=10.412(1)Å
α=105.22(1)° β=99.04(1)° γ=107.50(1)°
Compound X
C60H60Cl1N5O4P2Ru1S1
CrystEngComm (2014) 16, 30 7013
a=9.800(5)Å b=16.008(5)Å c=34.268(5)Å
α=90° β=90° γ=90°
Ctd_cwbpy
C55H56Cl1N5O9P2Ru1
CrystEngComm (2014) 16, 30 7013
a=10.432(1)Å b=20.600(3)Å c=27.012(5)Å
α=90° β=98.20(5)° γ=90°
C22H31ClO3
C22H31ClO3
CrystEngComm (2014) 16, 33 7802
a=7.48200(10)Å b=22.7510(3)Å c=36.2940(5)Å
α=90° β=90° γ=90°
C22H31ClO3
C22H31ClO3
CrystEngComm (2014) 16, 33 7802
a=7.48200(10)Å b=22.7510(3)Å c=36.2940(5)Å
α=90° β=90° γ=90°
Lamivudine_Hydrobromide
C8H12Br1N3O3S1
CrystEngComm (2015) 17, 28 5187
a=5.689(5)Å b=12.288(5)Å c=8.419(5)Å
α=90° β=103.897(5)° γ=90°
Lamivudine_Hydrofluoride
C8H12N3O3S,F2H
CrystEngComm (2015) 17, 28 5187
a=5.35980(10)Å b=12.0206(4)Å c=8.6306(3)Å
α=90° β=104.5500(10)° γ=90°
Lamivudine hydrochloride
C8H12N3O3S,Cl
CrystEngComm (2015) 17, 28 5187
a=6.0770(7)Å b=16.324(2)Å c=6.3440(7)Å
α=90° β=115.577(8)° γ=90°
Lamivudine_Hydrofluoride
C8H12N3O3S,F2H
CrystEngComm (2015) 17, 28 5187
a=5.43490(10)Å b=12.0714(3)Å c=8.6515(3)Å
α=90° β=103.854(2)° γ=90°
Lamivudine hydrogen phthalate
C8H12N3O3S,C8H5O4
CrystEngComm (2012) 14, 14 4562
a=5.39900(10)Å b=15.7550(4)Å c=20.6980(5)Å
α=90° β=90° γ=90°
Lamivudine salicylate monohydrate
C8H12N3O3S,C7H5O3,H2O
CrystEngComm (2012) 14, 14 4562
a=12.7246(12)Å b=5.2978(3)Å c=13.1688(9)Å
α=90° β=106.129(8)° γ=90°
Zalcitabine hydrochloride
C9H14N3O3,Cl
CrystEngComm (2014) 16, 30 7013
a=5.5482(2)Å b=12.0260(5)Å c=8.5725(3)Å
α=90.00° β=104.6393(24)° γ=90.00°
Lamivudine zalcitabine hydrochloride
C9H14N3O3,C8H12N3O3S,2(Cl)
CrystEngComm (2014) 16, 30 7013
a=6.692(1)Å b=8.886(1)Å c=10.412(1)Å
α=105.22(1)° β=99.04(1)° γ=107.50(1)°
Compound X
C60H60Cl1N5O4P2Ru1S1
CrystEngComm (2014) 16, 30 7013
a=9.800(5)Å b=16.008(5)Å c=34.268(5)Å
α=90° β=90° γ=90°
Ctd_cwbpy
C55H56Cl1N5O9P2Ru1
CrystEngComm (2014) 16, 30 7013
a=10.432(1)Å b=20.600(3)Å c=27.012(5)Å
α=90° β=98.20(5)° γ=90°
C10H8.98LaO8.99S2
C10H8.98LaO8.99S2
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=17.6665(5)Å b=22.7226(6)Å c=8.5749(3)Å
α=90° β=118.3200(10)° γ=90°
C10H9O9S2Sm
C10H9O9S2Sm
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=17.5594(7)Å b=22.4319(9)Å c=8.4604(2)Å
α=90° β=118.585(2)° γ=90°
C10H9O9PrS2
C10H9O9PrS2
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=17.5597(6)Å b=22.6337(7)Å c=8.5253(3)Å
α=90° β=118.362(2)° γ=90°
C52H46La2N4O16S4,3(O)
C52H46La2N4O16S4,3(O)
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=10.7422(4)Å b=17.1435(7)Å c=14.8397(6)Å
α=90° β=93.001(2)° γ=90°
C10H9NdO9S2
C10H9NdO9S2
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=17.5398(6)Å b=22.5802(7)Å c=8.5187(3)Å
α=90° β=118.427(2)° γ=90°
C22H15N2O8PrS2,3(H2O)
C22H15N2O8PrS2,3(H2O)
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=9.2708(2)Å b=11.9699(3)Å c=12.7725(3)Å
α=106.5890(10)° β=110.161(2)° γ=99.3770(10)°
C22H15N2NdO8S2,3(H2O)
C22H15N2NdO8S2,3(H2O)
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=9.2648(3)Å b=11.9499(3)Å c=12.7485(5)Å
α=106.629(2)° β=110.177(2)° γ=99.313(2)°
C22H15LaN2O8S2,3(H2O)
C22H15LaN2O8S2,3(H2O)
Dalton transactions (Cambridge, England : 2003) (2015) 45, 2 646-656
a=9.2906(14)Å b=12.025(2)Å c=12.835(2)Å
α=106.491(8)° β=110.125(9)° γ=99.551(9)°
4-(Pyridin-2-yl)pyrimidin-2-amine
C9H8N4
Acta Crystallographica Section C (2019) 75, 12
a=11.4608(15)Å b=5.3791(9)Å c=26.740(4)Å
α=90° β=91.457(12)° γ=90°
Potassium tetrachlorobis(dimethyl sulfoxide)iridate(III) monohydrate
K,C4H12Cl4IrO2S2,H2O
Acta Crystallographica Section B (2017) 73, 6 1032-1042
a=12.1963(2)Å b=7.4652(2)Å c=16.4793(4)Å
α=90° β=96.0550(10)° γ=90°
Potassium tetrachlorobis(dimethyl sulfoxide)iridate(III) 0.25-hydrate
K,C4H23Cl4IrO2S2,0.25(H2O)
Acta Crystallographica Section B (2017) 73, 6 1032-1042
a=12.7530(4)Å b=7.8356(2)Å c=15.3277(5)Å
α=90° β=111.581(2)° γ=90°
N-Butylammonium tetrachlorobis(dimethyl sulfoxide)iridate(III) hemihydrate
(C4H12Cl4IrO2S2),(C4H12N),0.5H2O
Acta Crystallographica Section B (2017) 73, 6 1032-1042
a=19.8210(4)Å b=10.0830(2)Å c=19.5720(5)Å
α=90° β=108.657(2)° γ=90°
Potassium tetrachlorobis(dimethylsulfoxide)iridate(III)
C4H12Cl4IrKO2S2
Acta Crystallographica Section B (2017) 73, 6 1032-1042
a=8.9902(7)Å b=15.1990(14)Å c=10.7569(9)Å
α=90° β=91.425(7)° γ=90°
4-bromo-N-(2-hydroxyphenyl)benzamide
C13H10BrNO2
Acta Crystallographica Section E (2014) 70, 12 o1261-o1262
a=23.4258(10)Å b=5.64730(10)Å c=9.2464(3)Å
α=90.00° β=93.0080(10)° γ=90.00°
2-(4-Chlorobenzamido)benzoic acid
C14H10ClNO3
Acta Crystallographica Section E (2015) 71, 11 o856-o857
a=26.8843(10)Å b=5.0367(2)Å c=20.9264(12)Å
α=90° β=117.489(2)° γ=90°
4-formyl-2-nitrophenyl 4-chloro-2-nitrobenzoate
C14H7ClN2O7
Acta Crystallographica Section E (2015) 71, 12 o940
a=7.7366(2)Å b=7.9480(2)Å c=12.6539(5)Å
α=90.0655(11)° β=100.3204(11)° γ=104.0633(12)°
(+-)-3-[(Benzo[<i>d</i>][1,3]dioxol-5-yl)methyl]-2-(3,4,5-trimethoxyphenyl)-1,3-thiazolidin-4-one
C20H21NO6S
Acta Crystallographica Section E (2014) 70, 12 o1235-o1236
a=15.3098(11)Å b=14.3677(12)Å c=8.6546(3)Å
α=90.00° β=97.429(4)° γ=90.00°
2-Nitro-<i>N</i>-(5-nitro-1,3-thiazol-2-yl)benzamide
C10H6N4O5S
Acta Crystallographica Section E (2014) 70, 12 o1252
a=9.6949(2)Å b=12.4192(2)Å c=9.8763(2)Å
α=90.00° β=94.9480(10)° γ=90.00°
5-nitro-2-furaldehyde N-(hydroxymethyl)semicarbazone
C7H8N4O5
Acta Crystallographica Section E (2005) 61, 7 o2099-o2101
a=10.3757(5)Å b=10.8125(5)Å c=16.9455(8)Å
α=90° β=92.095(3)° γ=90°
C16H9NO4,CH4O
C16H9NO4,CH4O
Acta Crystallographica Section E (2003) 59, 6 o820-o822
a=6.5606(3)Å b=7.3493(3)Å c=15.3575(7)Å
α=79.724(2)° β=78.980(2)° γ=74.194(5)°
C2H4N2NiS4
C2H4N2NiS4
Acta Crystallographica Section E (2003) 59, 2 m77-m79
a=7.1310(4)Å b=12.9170(8)Å c=10.9590(5)Å
α=90° β=130.293(3)° γ=90°
C14H13NO4
C14H13NO4
Acta Crystallographica Section E (2003) 59, 10 o1503-o1505
a=7.24290(10)Å b=10.4418(2)Å c=15.4618(3)Å
α=90° β=94.3530(10)° γ=90°
C16H20O5
C16H20O5
Acta Crystallographica Section E (2003) 59, 10 o1575-o1577
a=23.3022(3)Å b=10.2248(2)Å c=15.0785(3)Å
α=90° β=122.2730(10)° γ=90°
C13H10O5
C13H10O5
Acta Crystallographica Section E (2003) 59, 10 o1506-o1508
a=16.9357(5)Å b=4.36690(10)Å c=16.2558(4)Å
α=90° β=117.2180(10)° γ=90°
Bis(diphenylphosphinato-κO)bis(diphenylphosphinic acid-κO)bis(pyridine-κN)mercury(II)
C58H52HgN2O8P4
Acta Crystallographica Section E (2006) 62, 4 m816-m818
a=9.4511(3)Å b=12.3528(5)Å c=12.6391(4)Å
α=101.853(2)° β=109.278(2)° γ=95.797(2)°
C9H8N2O2
C9H8N2O2
Acta Crystallographica Section E (2003) 59, 5 o723-o725
a=5.6672(3)Å b=18.0609(11)Å c=8.1949(5)Å
α=90° β=99.135(3)° γ=90°